参芪扶正注射液联合曲普瑞林治疗晚期前列腺癌的临床研究

目的探讨参芪扶正注射液联合曲普瑞林治疗晚期前列腺癌的治疗效果及安全性。方法选取2015年3月—2016年3月在重庆市开州区人民医院就诊的晚期前列腺癌患者83例,随机分为对照组(42例)和治疗组(41例)。对照组皮下注射注射用醋酸曲普瑞林,3.75 mg/次,3周/次。治疗组在对照组治疗基础上静脉滴注参芪扶正注射液,250 m L/次,1次/d,3周1个疗程。两组均间歇1周进行下一个疗程,两组连续治疗6个疗程。治疗后,观察两组的临床疗效、局部控制率、总生存率。比较两组治疗前后血清前列腺特异性抗原(PSA)、血清睾酮(T)、KPS评分的变化情况。结果治疗后,对照组和治疗组的总有效率分别为71.43%、85.37%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者PSA、T水平均明显下降,同组治疗前后比较差异有统计学意义(P0.05);治疗后,治疗组PSA、T水平显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,对照组和治疗组KPS评分改善率分别为35.13%、52.50%,两组比较差异具有统计学意义(P0.05)。治疗后,对照组和治疗组的局部控制率分别为52.38%、82.93%,两组的总生存率分别为80.95%、97.56%,两组局部控制率、总生存率比较差异具有统计学意义(P0.05)。结论参芪扶正注射液联合曲普瑞林治疗晚期前列腺癌具有较好的临床疗效,可降低PSA和T水平,降低不良反应发生率,具有一定的临床推广应用价值。

Clinical study on Shenqi Fuzheng Injection combined with triptorelin in treatment of advanced prostate cancer

Objective To explore the therapeutic effect and safety of Shenqi Fuzheng Injection combined with triptorelin in treatment of advanced prostate cancer. Methods Patients (83 cases) with advanced prostate cancer in Kaizhou District People''s Hospital in Chongqing from March 2015 to March 2016 were randomly divided into control (42 cases) and treatment (41 cases) groups. Patients in the control group were sc administered with Triptorelin Acetate for injection, 3.75 mg/time, three weeks/time. Patients in the treatment group were iv administered with Shenqi Fuzheng injection, 250 mL/time, once daily, and 3 weeks were as 1 course of treatment. Patients in two groups were treated for 6 courses. After treatment, the clinical efficacy, local control rate, and total survival rate were evaluated, and the changes of PSA, T and KPS score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 71.43% and 85.37%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of PSA and T in two groups were decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of PSA and T in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the KPS score improvement rate in the control and treatment groups were 35.13% and 52.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, the local control rate in the control and treatment groups were 52.38% and 82.93%, respectively, total survival rates in two groups were 80.95% and 97.56%, and there was difference between two groups (P < 0.05). Conclusion Shenqi Fuzheng Injection combined with triptorelin has clinical curative effect in treatment of advanced prostate cancer, can reduce the levels of PSA and T, and can reduce the incidence of adverse reactions, which has a certain clinical application value.